There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Allogene Therapeutics Inc. (ALLO) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $4.11. The Allogene Therapeutics Inc. has recorded 532,602 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Allogene Therapeutics Announces Participation in September Investor Conference.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $4.11 and fluctuated between $4.1350 as its day high and $3.9450 as its day low. The current market capitalization of Allogene Therapeutics Inc. is $675.44M. A total of 2.46 million shares were traded on the day, compared to an average of 2.63M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, ALLO has seen 6 BUY and 1 SELL insider trades, representing the acquisition of 719,166 and the disposition of 10,000 shares. Over the last 12 months, there were 14 BUYs and 10 SELLs from insiders. Insiders purchased 4,421,645 shares during that period but sold 129,232.
In the most recent transaction, Mayo Stephen sold 10,000 shares of ALLO for 4.29 per share on Aug 07. After the transaction, the Director now owns 25,328 company shares. In a previous transaction on Feb 13, Bhavnagri Veer sold 3,000 shares at 6.85 per share. ALLO shares that General Counsel owns now total 577,677.
Among the insiders who sold shares, Bhavnagri Veer disposed of 3,000 shares on Jan 17 at a per-share price of $7.04. This resulted in the General Counsel holding 580,677 shares of ALLO after the transaction. In another insider transaction, Bhavnagri Veer sold 5,602 shares at $7.53 per share on Dec 15. Company shares held by the General Counsel now total 583,677.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ALLO in the last 3 months, the mean price target is $16.13 with high estimates of $35.00 and low estimates of $5.00. In terms of 52-week highs and lows, ALLO has a high of $15.56 and a low of $3.70.
As of this writing, ALLO has an earnings estimate of $Allogene Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Ally Financial Inc. estimates, with a high estimate of $Allstate Corporation (The) per share and a lower estimate of $Alto Ingredients, Inc.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ALLO’s latest balance sheet shows that the firm has $809.48M in Cash & Short Term Investments as of fiscal 2021. There were $69.93M in debt and $48.17M in liabilities at the time. Its Book Value Per Share was $4.24, while its Total Shareholder’s Equity was $916.41M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.41.